Vertex Pharmaceuticals has agreed to an exclusive four-year global research collaboration with Verve Therapeutics to discover and develop an in vivo gene editing program for liver disease. Verve will conduct the preclinical development, and Vertex will provide $60 million in funding and will be responsible for subsequent development, manufacturing and commercialization. Verve is eligible to receive payments of up to $66 million for success and up to $340 million during the development and commercialization phase, as well as tiered royalties from sales.